FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

VIP

Vasoactive Intestinal Peptide / Aviptadil

Cognitive & Neuro

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide originally isolated from porcine intestinal tissue that functions as a potent vasodilator, immunomodulator, and neurotransmitter throughout the body. It has gained significant research attention for its potential role in treating Chronic Inflammatory Response Syndrome (CIRS) associated with mold illness, as well as pulmonary arterial hypertension. VIP is typically administered via nasal inhalation in clinical research settings, though injectable forms also exist.

작용 메커니즘

Endogenous 28-amino-acid neuropeptide with broad physiological roles. Potent vasodilator, bronchodilator, and immunomodulator. Promotes neuronal survival, regulates circadian rhythm via SCN, inhibits NF-kB-mediated inflammation, and modulates gut-brain axis signaling.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 50-200mcg intranasally 1-3 times daily. IV research doses used in ARDS studies were 100-300pmol/kg/min. Subcutaneous protocols not well-established due to rapid degradation.

연구 노트

Clinical Research Status

VIP has been studied extensively in the context of CIRS by Dr. Ritchie Shoemaker and others, with intranasal administration showing improvements in inflammatory markers and pulmonary artery pressures. Research in pulmonary hypertension has demonstrated VIP's ability to reduce pulmonary vascular resistance and improve exercise capacity in small clinical trials. It is not FDA-approved for any indication, and its use remains investigational with ongoing debate about optimal dosing protocols.

Key Published Findings

Studies demonstrate VIP's ability to downregulate inflammatory cytokines including TGF-beta, MMP-9, and complement split products C3a and C4a in CIRS patients. In pulmonary hypertension models, VIP reduces right ventricular systolic pressure and pulmonary vascular remodeling through cAMP-mediated smooth muscle relaxation. Neuroprotective properties have been documented in models of Parkinson's disease and Alzheimer's disease through anti-inflammatory and anti-apoptotic mechanisms.

Safety Profile

VIP is generally well-tolerated at therapeutic doses, with the most common side effects being nasal congestion, flushing, and transient hypotension due to its vasodilatory properties. Diarrhea and abdominal cramping may occur at higher doses, reflecting its original physiological role in gut motility regulation. Caution is warranted in patients with existing hypotension or those on antihypertensive medications due to additive blood pressure lowering effects.

Comparison to Related Compounds

VIP belongs to the secretin/glucagon superfamily and shares structural homology with PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), though VIP has greater selectivity for VPAC1 and VPAC2 receptors. Unlike synthetic vasodilators, VIP provides combined anti-inflammatory and vasodilatory effects through a single molecular pathway. Compared to other CIRS treatments in the Shoemaker protocol, VIP is typically used as a final-step intervention after other markers have been normalized.

Community Observations

Patients using VIP for CIRS report improvements in fatigue, cognitive function, and respiratory symptoms, often describing it as the final piece in their recovery protocol. Sourcing pharmaceutical-grade VIP remains challenging, and proper cold-chain storage is critical for maintaining peptide stability. Some users report rebound symptoms upon discontinuation, suggesting the need for gradual tapering or ongoing maintenance dosing.

반감기

~1-2 minutes (IV); ~30 min (intranasal)

재조성

Sterile saline for IV; saline for nasal spray

보관

건조한 상태

Store at -20C. Extremely sensitive to degradation.

재조성된 상태

Prepare fresh. Use within hours of reconstitution.

미국 법적 상태

Research chemical (in clinical trials for ARDS)

또는 알려진 이름으로

Vasoactive Intestinal PeptideAviptadil

자주 묻는 질문

VIP란 무엇인가요?

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide originally isolated from porcine intestinal tissue that functions as a potent vasodilator, immunomodulator, and neurotransmitter throughout the body. It has gained significant research attention for its potential role in treating Chronic Inflammatory Response Syndrome (CIRS) associated with mold illness, as well as pulmonary arterial hypertension. VIP is typically administered via nasal inhalation in clinical research settings, though injectable forms also exist.

VIP는 어떻게 작용하나요?

Endogenous 28-amino-acid neuropeptide with broad physiological roles. Potent vasodilator, bronchodilator, and immunomodulator. Promotes neuronal survival, regulates circadian rhythm via SCN, inhibits NF-kB-mediated inflammation, and modulates gut-brain axis signaling.

VIP의 미국 규제 현황은 어떤가요?

Research chemical (in clinical trials for ARDS)

VIP의 반감기는 얼마인가요?

~1-2 minutes (IV); ~30 min (intranasal)

VIP의 다른 이름은 무엇인가요?

Vasoactive Intestinal Peptide, Aviptadil

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기